


# ARTIFICIAL INTELLIGENCE (AI) AND PRECISION MEDICINE: DOES THE HEALTH ECONOMIST NEED TO ADAPT TO THE MACHINE?

Augustin Terlinden, MSc, Actuary and Health Economist  
Patricia A Deverka, MD, MS, MBE, Principal Researcher  
Amine Aissaoui, PhD, MSc, Researcher  
Olivier Ethgen, MSc, PhD, Scientific Director

ISPOR 23rd Annual International Meeting  
May 21, 2018



## Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning

Ryan Poplin<sup>1,2</sup>, Avinash V. Venkatasubramanian<sup>1,2</sup>, Katy Blumer<sup>1</sup>, Yun Liu<sup>1</sup>, Michael V. McConnell<sup>1,3</sup>, Greg S. Corrado<sup>1</sup>, Lily Peng<sup>1,2</sup> and Dale R. Webster<sup>1,2</sup>

Traditionally, medical discoveries are made by observing associations, making hypotheses from them and then designing and testing experiments to test the hypotheses. However, with medical images, observing and quantifying associations can often be difficult because of the wide variety of features, patterns, textures and shapes that are present in real data. Here, we show that deep learning can extract new knowledge from retinal fundus images. Using deep-learning models trained on data from 284,120 patients and validated on two independent datasets of 11,626 and 914 patients, we predicted cardiovascular risk factors not previously thought to be present or quantifiable in retinal images, such as age (mean absolute error within 3.26 years), gender (area under the receiver operating characteristic curve (AUC) = 0.87), smoking status (AUC = 0.70), systolic blood pressure (mean absolute error within 11.21 mmHg) and major adverse cardiac events (AUC = 0.26). We also show that the trained deep-learning models used anatomical features, such as the optic disc or blood vessels, to generate each prediction.

NATURE BIOMEDICAL ENGINEERING | VOL 2 | MARCH 2018 | 158-164 | www.nature.com/naturebioengineering

### CONCLUSION

Artificial intelligence predicts cardiovascular risk factors based on retinal images.

# AGENDA

- How AI relates to Precision Medicine
- Introduction to AI
- AI-backed precision medicine
  - An illustration: skin cancer detection
  - A definition
  - Advantages and challenges
  - Market access considerations
- Real-life examples
  - Cardiac arrhythmias detection
  - Lung cancer detection
  - Diabetic retinopathy detection
- Impact on health economics
- Conclusion



Feb 3rd 2018

3

## HOW AI RELATES TO PRECISION MEDICINE

4

# PRECISION MEDICINE


- **Definition** – an emerging approach for disease prevention and treatment that takes into account people’s individual variations in genes, environment and lifestyle (NIH)
- **Personalized medicine** – an older term that can be misinterpreted to imply treatments and preventions are uniquely developed for each individual (NRC) Still continues to be used interchangeably by some people

5

## AI-enabled Precision Medicine


- AI is an important enabler of PM
- Primarily for big data analytics
  - Analyze large medical data sets
  - Draw conclusions
  - Find new correlation based on existing precedences
  - SUPPORT the doctor’s job in decision-making

6



## Relationship of AI to Precision Medicine

- Make patients the point of care
- Create vast amounts of data that require advanced analytics
- Establish the foundation of precision medicine
- AI is key technology that can bring these opportunities to everyday practice



- ## Challenges
- Need to create ethical standards
  - Incremental development to evaluate all implications
  - Medical professionals need to learn how AI works in practice
  - Patients need to become accustomed
  - Decision-makers need to assess effectiveness


## What is required

- Patient-centric approach
- Appropriate regulatory framework
- Appropriate ethical framework to proactively address ethical challenges
- Consumer education


9

## **A QUICK INTRODUCTION TO AI**

10



11




[www.searchcrm.techtarget.com/definition/voice-recognition](http://www.searchcrm.techtarget.com/definition/voice-recognition)

12



Gatys LA and al., A Neural Algorithm of Artistic Style, 2015



$$Y = f(X)$$

CARDIOVASCULAR  
RISK

Risk Factor	Parameter Estimate	P-Value	Hazard Ratio (HR) (95% CI for HR)
Age, years	0.11691	0.0001	1.134 (1.111-1.138)
Male Sex	0.40358	0.0002	1.497 (1.215-1.845)
Systolic Blood Pressure	0.01645	0.0001	1.017 (1.012-1.021)
Current Smoker	0.76798	0.0001	2.155 (1.758-2.643)
Total Serum Cholesterol	-0.00209	0.0963	0.998 (0.995-2.543)
Diabetes	-0.02385	0.1585	0.818 (0.615-1.083)




A smoker has twice the chance of developing a CV event as compared to a non-smoker  
(the other parameters being the same)

Source: Framingham CVD risk estimate, Lisa Sullivan, Boston University School of Public Health, 2016

15

## LINEAR REGRESSION




**LINEAR RELATIONS** between **X**

$$Y = w_0 + w_1 \cdot X_1 + w_2 \cdot X_2 + w_3 \cdot X_3$$

Interpretability	Predictive power
<b>HIGH</b> "We, poor humans, need to see"	<b>Low</b> Because most real-life optimization problems are non linear

16

# The curse of high dimensionality




$$Y = f(X_1, X_2, X_3, \dots, X_{1,000,000,000})$$

*Is linear regression sufficient here?*

17

# DEEP LEARNING



**NON LINEAR RELATIONS** between **X**

$$Y = \frac{1}{1 + e^{-\left( w_0 + w_1 \cdot \frac{1}{1 + e^{-(w'_0 + w'_1 \cdot X_1 + w'_2 \cdot X_2 + w'_3 \cdot X_3)}} + w_2 \cdot \frac{1}{1 + e^{-(w_0' + w_1' \cdot X_1 + w_2' \cdot X_2 + w_3' \cdot X_3)}} \right)}}$$

Interpretability	Predictive power
Low	HIGH

**This extra performance comes at the cost of interpretability!**

18

# AI-BACKED PRECISION MEDICINE

19

## SKIN CANCER DETECTION


### SKIN CANCER (in US)

- 5.4 million new cases / year


### MELANOMAS (in US)

- Fewer than 5% of all skin cancers
  - 75% of all skin-cancer-related deaths (10,000 deaths annually)
  - 5-year survival rate
    - 99% if detected in its earliest stages
    - 14% if detected in its latest stages
- Early detection is critical

Source: Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S. Dermatologist-level classification of skin cancer with deep neural networks. *Nature*. 2017 Feb 2;542(7639):115–118.




# 130,000 labelled clinical images



21

## A simple image processing technique




22


GoogleNet Inception v3 CNN


Pre-defined algorithm is **pre-trained** on non-health-specific images!

1.28 million images (1,000 object categories) from the 2014 ImageNet Large Scale Visual Recognition Challenge



## Training and test






**OBSERVATIONS (from the last layer)**

- We see clusters of points of the same clinical classes
- Benign classes are separated from their malignant counterparts

25

## PERFORMANCE

Melanoma: 111 dermoscopy images



$$\text{sensitivity} = \frac{\text{true positive}}{\text{positive}}$$

$$\text{specificity} = \frac{\text{true negative}}{\text{negative}}$$

### CONCLUSION


The machine is on par with the performance of the dermatologists and outperforms the average.

26

# AI-BACKED PRECISION MEDICINE

Definition

This is NOT ...



27

# AI-BACKED PRECISION MEDICINE

Definition


## PRECISION MEDICINE

Medical decisions are tailored to patient characteristics.

## ARTIFICIAL INTELLIGENCE

Device that mimics human learning and reasoning.

Machine that can advise a patient with health behaviors ... without human supervision!




28

# AI-BACKED PRECISION MEDICINE

	ADVANTAGES	DRAWBACKS
<b>Manufacturer</b>	<ul style="list-style-type: none"> <li>- Shorter time, less expensive and less risky development (From 10 years – pill – to a few days – app – to reach the market)</li> <li>- <b>High-performance tool</b> (Sensitivity and specificity)</li> </ul>	<ul style="list-style-type: none"> <li>- Performance are data-dependent (Asthma understood by AI as a protective factor for pneumonia whereas the original study advised asthma patients to be treated in ICU)</li> <li>- <b>Lower interpretability</b> (« Black box » model)</li> <li>- Stronger competition (40,000 health-related apps are today available)</li> </ul>
<b>Payer</b>	<ul style="list-style-type: none"> <li>- <b>Higher detection of false positive</b> (Those often result in unnecessary invasive biopsies) and <b>false negative</b> (More lives are saved)</li> <li>- Easier to set up performance-based risk sharing agreement (Cheaper post-launch studies)</li> </ul>	<ul style="list-style-type: none"> <li>- Tests might be expensive</li> <li>- Tests might be over-/under-prescribed</li> </ul>
<b>Physician</b> Ophthalmology Otolaryngology (ENT) Radiology	<ul style="list-style-type: none"> <li>- Augmented clinical decision-making for specialists</li> <li>- <b>Limited time dedicated by the specialist</b></li> </ul>	<ul style="list-style-type: none"> <li>- <b>“Deskilling” = human expertise likely to disappear</b> (14% decrease in diagnostic sensitivity when human readers are facing computer-aided detection)</li> <li>- <b>“Demise of context” = lack of ability to assess patients holistically</b> (Only visual and dermoscopic inspection of a skin lesion)</li> </ul>
<b>Patient</b>	<ul style="list-style-type: none"> <li>- Reaching underserved communities (6.3 billion smartphones will exist by 2021)</li> <li>- Health-promoting behaviors</li> </ul>	<ul style="list-style-type: none"> <li>- Data privacy (Sensitive patient information and data security breaches)</li> <li>- Responsibility (in case of false positive diagnosis ...)</li> </ul>

Cabitza F, Rasoini R, Gensini GF. Unintended Consequences of Machine Learning in Medicine. *JAMA*. 2017;318(6):517–518. doi:10.1001/jama.2017.7797

## Regulatory overview



<https://www.wired.com/2017/05/medicine-going-digital-fda-racing-catch/>  
U.S. Food and Drug Administration. (2015). What is a medical device? U.S. Food and Drug Administration. 28 December [online]. Available at <https://www.fda.gov/AboutFDA/Transparency/Basics/ucm211822.htm> [Accessed 09 October 2017].

# H2020 program – 7.5b€ to position EU as a top healthcare actor in the world

**H2020 3<sup>rd</sup> Health Programme**

**Personalised medicine**

- Microbiome
- Data driven-in silico models
- Mechanisms of co-morbidities
- Combinatorial therapies
- Collaboration with Canada on "human data"
- Pilots of implementation of personalised medicine
- Actions in support of ICherMed
- Rare Diseases

**Digital transformation in health and care**

- In silico medicine
- Personal Health Record/Electronic Health Record
- **Big data and Artificial Intelligence**
- Univocal identification of medicines
- Cyber Security in health and care

**Innovative health and care systems- Integration of care**

- Patient centred approaches palliative care/Eoofl
- HTA research to support evidence-based healthcare

**Innovative health and care industry**

- Innovation platforms for ATMPs
- Regenerative medicine
- Strengthen regulatory science supporting advice

**Infectious diseases**

- New anti-infective agents for NID
- HIV/TB/HCV in collaboration with Russia
- Stratified hosted directed approaches
- EU clinical research network

**Improving global health**

- Coordination of EU brain research
- Maternal and child health
- Strategic collaboration with China
- Prevention and management of hypertension and/or diabetes

8. OPEN JMD DAY Horizon 2020 'Health, demographic change and wellbeing

13 December 2017

31

## Clinical guidelines

**Radiology**

**Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction<sup>1</sup>**

Seong Ho Park, MD, PhD  
Kyunghwi Han, PhD

2018

The use of artificial intelligence in medicine is currently an issue of great interest, especially with regard to the diagnostic or predictive analysis of medical images. Adoption

Definition of a performance metric for AI-based medical diagnostic tool

- Sensitivity
- Specificity

## Payer overview

Today, AI generates traction among payer bodies in Europe

New guidelines are being set up

→ Illustration: NIA and Alivecor



33

## REAL-LIFE EXAMPLES

34


# Alivecor and atrial fibrillations

## ATRIAL FIBRILLATIONS

- Irregular heart rhythm that is often abnormally fast
- 5-fold increase in the risk of stroke and 50% more at risk of death

## AI SOLUTION

- Heart rate/activity discordance identifies times when a user should take an ECG.



There is a complex “non-linear” relation between heart rate and activity




Heart rate was outside the range which AliveCor predicted for the level of activity at that time.

35




*We looked at the UK system*

...



# NICE Headlights



From NICE: Lowres N and al., Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014 Jun

37

# Scottish Highlights

Simulation of the cumulative costs and life years of a cohort over a 30 year horizon

Strategy	Cost, £	Incremental cost, £	QALYs	Incremental QALYs	ICER
AliveCor	1,922.93	83.05	9.5496	-0.0160	-
Usual Care	2,005.98		9.5336		Dominated



AliveCor arm costs less than the comparator arm



AliveCor arm brings more QALYs than the comparator arm

**Main assumptions**

- High-risk population
- Patients in the comparator arm did not receive screening
- Screening with AliveCor costs £22.02 per patient screened.

38

# Pricing in the US

- Mostly NOT currently reimbursed by private insurers or Medicare
  - Eligible for payment with a Flexible Spending Account, Health Savings Account or Health Reimbursement Arrangement
  - Physicians who purchase device for use in office or bedside can submit for reimbursement with CPT code for 1-3 lead rhythm ECG with interpretation and reports
- Mostly sold directly to consumers (DTC)
  - One-time charge of \$99 for basic service
  - Premium service for \$10 a month (or \$100 a year)
    - Includes features such medication tracking, unlimited storage, history of heart health data and the ability for customers to email EKGs to themselves and their doctors.

39


# Enlitic and lung cancers

## LUNG CANCERS

- 80% of patients in late-stages die
- If caught early, survival is nearly 10 times more likely
- Hardest cancer to detect in medical images

## AI SOLUTION

- AI detects lung cancer nodules in chest CT images 50% more accurately than an expert panel of thoracic radiologists
- AI speed is 50,000 times faster than a human radiologist



## ENLITIC

- Founded in 2014, \$15 millions in funding
- Current positioning: AI technology "enables" radiologists (and do not replace them).
- Business model: take a cut of the profits realized by the clients that adopt the solution



Avoided biopsies and cancer-related events

\$9 billions being spent in on radiologists

- Average radiologist's salary is \$286,000 a year
- 1 radiologist per 10,000 people → 31,800 radiologists in the US

<https://www.enlitic.com/press-release-10272015.html>

40

# IDx-DR and diabetic retinopathy

## DIABETIC RETINOPATHY

- If uncaught early, diabetic retinopathy can lead to vision loss.
- 50 percent of diabetic patients do not see their eye doctor on a yearly basis

## AI SOLUTION

- FDA wanted sensitivity > 85% and specificity > 82.5%.
- IDx-DR passed the bar, with rates of 87.4% and 89.5 % percent, respectively.



"(...) IDx-DR makes a clinical decision, without someone like me being involved — it's fully autonomous."

Michael Abràmoff, ophthalmologist and CEO

FDA News Release

## FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems

Facebook | Twitter | LinkedIn | YouTube | Instagram | RSS

For Immediate Release

April 11, 2018

Unlike other AI-based tools, IDx-DR is designed to make a directive, not a recommendation.


<https://medcitynews.com/2018/02/ai-screening-tool-diabetic-retinopathy-makes-decision-not-recommendation/> <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604357.htm>

41

## IMPACT ON HEALTH ECONOMICS


42

# Redefining the standard of care




43

# New claims of interest



44

# Increasing relative performance of AI-based PM tools over time



45

## CONCLUSION

46

# CONCLUSION

## NEW TECHNOLOGY

- Lower interpretability
- Higher performance
  - Sensitivity
  - Specificity

## IMPACT ON MARKET ACCESS

- Regulatory
  - New skills needed
  - New way of thinking
- Payers
  - [On the short run] Cost burden will decrease
    - Less specialists
    - Shorter time dedicated by the specialist
    - Less disease-related event
    - Reduced waste of resources
  - [On the long run] Cost burden might increase
    - Lock-in effect
    - Pricing power

47


## Q&A

48

# Responsibility

In case the machine goes wrong, who is responsible?

What about the case where the standard-of-care algorithm would have saved the patient?



49

# Data security

When you undergo diagnostic tests to determine the best way to treat your skin cancer, are you concerned your sensitive information will be collected by a machine?

50

## Being a health economist

*In your opinion*, if IA-based precision medicine tools enter the playground tomorrow, how would health economics be impacted?